EHD2 and breast cancer: Across BC subtypes, the high cytoplasmic and nuclear-negative EHD2, which also predicted shorter BC-specific survival (Figure 3—figure supplement 1), was seen in about half of TNBC and HER2 + samples, and a third of ER + samples (Figure 3C, Supplementary file 1-Table 1B).